288 Participants NeededMy employer runs this trial

Group Medical Visits for Dyslipidemia

(PARTAGE-D Trial)

MB
Overseen ByMathieu Belanger, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Université de Sherbrooke
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests group medical visits to help individuals with dyslipidemia (unhealthy cholesterol levels) manage their condition more effectively. These visits will guide participants in making lifestyle changes to enhance heart health and overall well-being. Participants will attend sessions with healthcare professionals, such as doctors and dietitians, to learn and set personal health goals. The trial seeks individuals diagnosed with dyslipidemia who have a moderate risk of heart issues. Those who find it challenging to participate in group activities may not find this trial suitable. As an unphased trial, it offers an opportunity to explore innovative ways to manage the condition and improve quality of life.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that group medical visits are safe for patients with dyslipidemia?

A previous study showed that group medical visits (GMVs) are safe and well-tolerated by patients. GMVs involve sessions where patients meet with healthcare professionals to learn about and discuss health topics. These sessions typically include activities like setting health goals and socializing, all aimed at improving health habits.

Research on GMVs for various health conditions indicates they do not cause significant negative effects. The focus is on lifestyle changes, which are generally low-risk. Patients often report positive experiences, with better health management and improved quality of life.

Although specific data for GMVs in patients with dyslipidemia (an imbalance of fats in the blood) is lacking, the approach mirrors that used in other conditions where GMVs have been safely implemented. Overall, evidence suggests GMVs are a safe option for supporting lifestyle changes.12345

Why are researchers excited about this trial?

Researchers are excited about Group Medical Visits (GMVs) for dyslipidemia because they offer a fresh approach to managing this condition through lifestyle medicine, which is different from traditional medication-based treatments like statins. Unlike standard care that often focuses on individual appointments, GMVs bring patients together in small groups, encouraging peer support and motivation. These sessions are led by a team of health professionals, including dietitians and psychologists, who guide patients in setting achievable health goals and provide personalized advice. This team-based, interactive method may empower patients to take charge of their health in a more holistic way, which is why researchers are eager to explore its potential benefits.

What evidence suggests that group medical visits are effective for dyslipidemia?

Studies have shown that group medical visits (GMVs) can improve health for people with various conditions, including cholesterol problems linked to heart disease. In this trial, participants in the intervention group will receive regular care supplemented by GMVs. Research indicates that involving different health professionals in GMVs leads to better cholesterol management. For example, one study found that family-based programs, similar to GMVs, significantly improved cholesterol levels by lowering bad cholesterol (LDL) and raising good cholesterol (HDL). Another article noted that 78.1% of patients reached their cholesterol goals with a structured approach. These findings suggest that GMVs might effectively manage cholesterol issues by combining expert care with peer support.12678

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with dyslipidemia (unhealthy cholesterol levels) who have at least a moderate risk of heart disease. People can't join if they have severe mental health issues, are unable to attend group sessions or give consent, or have a terminal illness with less than one year to live.

Inclusion Criteria

I have high cholesterol and an intermediate risk of heart disease.

Exclusion Criteria

I do not have a severe mental health condition that would prevent me from joining group sessions.
I am able to join group sessions and give my consent.
I have a terminal illness or my life expectancy is less than 12 months.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Group Medical Visits (GMVs)

Participants attend a series of group medical visits focusing on lifestyle medicine for dyslipidemia management. Each series includes eight sessions of 90-120 minutes.

9-12 months
8 sessions (in-person)

Follow-up

Participants are monitored for changes in lipid profiles and other health outcomes after the GMVs.

12 months

Maintenance

Assessment of the willingness of physicians and clinic managers to continue offering GMVs and monitoring the number of GMVs delivered.

24 months

What Are the Treatments Tested in This Trial?

Interventions

  • Group Medical Visits

Trial Overview

The study is testing group medical visits—where patients meet together with healthcare providers—to see if this approach helps improve lifestyle habits and cholesterol levels in people with dyslipidemia.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Intervention groupExperimental Treatment1 Intervention
Group II: Usual care groupActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Université de Sherbrooke

Lead Sponsor

Trials
317
Recruited
79,300+

Citations

Group Medical Visits for Patients With Dyslipidemia

Effectiveness will be assessed by administering pre- and post-GMV questionnaires to measure changes in patient knowledge, self-efficacy, ...

Family-based interventions for optimal lipid outcomes in ...

At 24 months, intervention improved lipids: ↓TC −24, ↓LDL-C −14, ↑HDL-C +7, ↓TGL −9 mg/dL. •. Scalable family-centered strategies may reduce ...

Adherence to Lipid-Lowering Therapy and Reaching ... - PMC

Self-reported adherence to lipid-lowering therapy in youth is excellent and was associated with achieving goal LDL-C goals.

ACC 2026: Intensive Lipid Lowering for High-Risk ...

One year post-ASCVD event, those with a baseline LDL-C of 70 mg/dL who successfully maintained this level had a 22.2% reduced risk of myocardial ...

A National Lipid Association Expert Clinical Review

The evidence that is available consistently supports that a multidisciplinary approach to lipid management leads to better outcomes. Examples include ...

Dyslipidemia management for primary prevention of ... - PMC

Dyslipidemia is a fundamental risk factor for cardiovascular diseases (CVDs) and can worsen the prognosis, if unaddressed. Lipid guidelines are still evolving ...

Variation in Lipid Management for Atherosclerotic ...

Electronic health record data from patients with atherosclerotic cardiovascular disease between January 1, 2021, and December 31, 2023, ...

New guidance recommends a new approach to assess ...

The algorithms will allow clinicians to take a more precise approach to reducing cardiovascular risk in patients with high LDL cholesterol ...